Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Sets Groundwork For Rapid Expansion In China Through R&D Partnerships

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Roche is laying the groundwork for a major new phase in expansion across China through partnerships with promising pharmaceutical research outfits and biotechnology start-ups, according to senior Roche executives

You may also be interested in...



Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams On Seeking More Innovation In China And Korea: An Interview With PharmAsia News (Part 1 of 2)

Roche recently expanded its investment in innovation in Asia by opening its fourth Global Partnering office in Shanghai. Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams sat down with PharmAsia News' Shanghai Bureau to talk about the mission of the newly established partnering site and Roche's partnering strategies in Asia.

Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams On Seeking More Innovation In China And Korea: An Interview With PharmAsia News (Part 1 of 2)

Roche recently expanded its investment in innovation in Asia by opening its fourth Global Partnering office in Shanghai. Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams sat down with PharmAsia News' Shanghai Bureau to talk about the mission of the newly established partnering site and Roche's partnering strategies in Asia.

Roche Seeks Partnerships, Innovation In China Rather Than Outsourcing

Novel targets that are best and first in class with solid IP and potential to change standard of care qualify as partnering opportunities.

Related Content

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel